Chronic Kidney Disease: eGFR Stages, Albuminuria, and SGLT2 Protection

The Silent Epidemic in Kidney Medicine

Chronic kidney disease (CKD) affects an estimated 850 million people worldwide — more than diabetes and cancer combined — yet up to 90% of those affected remain unaware of their diagnosis until the disease has advanced significantly. In the United States, approximately 37 million adults carry a CKD diagnosis, and CKD is the ninth leading cause of death. The condition is defined as structural or functional kidney abnormalities persisting for more than 3 months, affecting health. Its progression is silent precisely because the kidneys possess enormous functional reserve: symptoms typically emerge only after more than 60% of kidney function has been lost.

CKD amplifies risk across organ systems. Patients with advanced CKD have cardiovascular mortality rates 10–20 times higher than age-matched controls — a greater excess risk than for any traditional cardiac risk factor. Managing CKD therefore requires simultaneous management of its cardiovascular, metabolic, and hematological complications.

eGFR-Based Staging: G1 Through G5

The estimated glomerular filtration rate (eGFR) — calculated from serum creatinine, age, sex, and race using the CKD-EPI 2021 equation — quantifies how much blood the kidneys filter per minute per 1.73 m² of body surface area. KDIGO (Kidney Disease: Improving Global Outcomes) guidelines classify CKD into five GFR categories:

An eGFR alone does not fully characterize CKD prognosis. The KDIGO heat map plots GFR categories against albuminuria categories, generating a combined prognosis grid from "green" (low risk) to "red" (very high risk) — recognizing that albuminuria provides independent and additive prognostic information beyond eGFR.

Albuminuria Categories

Albuminuria — protein leakage into urine — reflects glomerular damage and serves as both a diagnostic marker and treatment target.

The urine albumin-to-creatinine ratio (ACR) is preferred over 24-hour urine collections for initial screening due to convenience, though a single spot ACR can be affected by exercise, fever, or positional changes (orthostatic proteinuria). Two abnormal measurements separated by 3 months confirm persistent albuminuria required for diagnosis.

SGLT2 Inhibitors: Kidney Protection Beyond Glucose

The discovery that SGLT2 inhibitors protect kidney function independently of their glucose-lowering effects has transformed CKD management. Two pivotal trials define the evidence base:

• CREDENCE trial (2019): Canagliflozin 100 mg daily vs. placebo in 4,401 patients with CKD (eGFR 30–90) and type 2 diabetes on maximum-tolerated renin-angiotensin system blockade. Primary endpoint (kidney failure, doubling of serum creatinine, or renal/cardiovascular death) reduced by 30%. The trial was stopped 1 year early due to overwhelming efficacy
• DAPA-CKD trial (2020): Dapagliflozin 10 mg in 4,304 patients with eGFR 25–75 and ACR ≥200, regardless of diabetes status. Reduced primary endpoint (sustained ≥50% eGFR decline, ESKD, or renal/CV death) by 39% — including a 29% reduction in patients without diabetes, confirming the renal benefit is independent of glucose lowering

Proposed kidney-protective mechanisms include reduced intraglomerular pressure (via tubuloglomerular feedback restoration), reduced glomerular hyperfiltration, decreased renal oxygen consumption, anti-inflammatory and anti-fibrotic effects, and reduced tubular workload through glycosuria. SGLT2 inhibitors are now recommended in KDIGO 2022 guidelines for all CKD patients with eGFR ≥20 and either diabetes or albuminuria ≥200 mg/g.

Dietary Management and Protein Restriction

Dietary protein restriction to 0.6–0.8 g/kg/day in CKD stages G3–G5 reduces accumulation of uremic solutes (urea, phosphate, potassium) and may slow GFR decline. The MDRD study (Modification of Diet in Renal Disease, 1994) showed modest benefit of very low protein diets in advanced CKD, though malnutrition risk limits aggressive restriction. Plant-based protein sources are preferred: they generate fewer uremic toxins and provide lower phosphorus bioavailability than animal proteins. Potassium restriction becomes relevant at eGFR <30 due to impaired renal excretion and hyperkalemia risk.

• Sodium restriction (<2.3 g/day) reduces blood pressure and proteinuria in CKD patients
• Phosphorus restriction limits hyperphosphatemia, a key driver of renal osteodystrophy and cardiovascular calcification in advanced CKD
• Bicarbonate supplementation (targeting serum bicarbonate 22–29 mEq/L) may slow CKD progression; metabolic acidosis accelerates muscle catabolism and protein degradation

Dialysis: Triggers and Modalities

Kidney replacement therapy (KRT) — hemodialysis, peritoneal dialysis, or transplantation — becomes necessary when CKD reaches stage G5 or when uremic symptoms develop. Absolute indications to initiate dialysis include uremic pericarditis, encephalopathy, refractory fluid overload, hyperkalemia, or persistent metabolic acidosis not controlled by medical management. The eGFR threshold for elective dialysis initiation typically falls between 5 and 10 mL/min/1.73 m², though the IDEAL trial demonstrated no benefit to early dialysis initiation at eGFR 10–14 compared to planned start at 5–7 — a finding that has shifted practice toward symptom-guided rather than eGFR-triggered initiation.

This article is for informational purposes only. Consult a qualified healthcare professional.